CoChat

Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumors

van Dongen, Minka, Savage, Nigel D.L., Jordanova, Ekaterina S., Briaire‐de Bruijn, Inge H., Walburg, Kimberley V., Ottenhoff, Tom H.M., Hogendoorn, Pancras C.W., van der Burg, Sjoerd H., Gelderblom, Hans, van Hall, Thorbald · 2010 · International Journal of Cancer
Cited by 118

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

We have made a detailed inventory of the immune infiltrate of gastrointestinal stromal tumors (GISTs), which originate from mesenchymal cells in the intestinal tract. These sarcomas are heavily infiltrated with macrophages and T cells, while immune cells of other lineages were much less abundant. Dissecting the functional subtypes of T cells with multicolor fluorescent microscopy revealed substantial populations of cytotoxic T cells, helper T cells and FoxP3+ regulatory T cells. The balance of cytotoxic T cells and FoxP3+ T cells was toward immune suppression. Analysis of the macrophage population also showed a dominance of anti‐inflammatory cells, as the M2 type scavenger receptor CD163 was abundantly present. Other subsets of macrophages (CD14+CD163−) were occasionally detected. M2 type CD163+ macrophages were associated with the number of infiltrating FoxP3+ regulatory T cells and twice as many macrophages were found in metastatic GIST compared to primary lesions. Most metastatic GISTs had been treated with the tyrosine kinase inhibitors imatinib and sunitinib, but the high macrophage infiltrate was not related to this treatment. However, imatinib and sunitinib did induce secretion of anti‐inflammatory IL‐10 in macrophage cultures, indicating that treatment with these inhibitors might contribute to an immune suppressive microenvironment in GIST. Overall, our data reveal a picture of GIST as an active site of tumor‐immune interaction in which suppressive mechanisms overrule potential antitumor responses. Tyrosine kinase inhibitors might promote this negative balance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.25113

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 118

Metadata

Authors
van Dongen, M., Savage, N. D. L., Jordanova, E. S., Briaire‐de Bruijn, I. H., Walburg, K. V., Ottenhoff, T. H. M., Hogendoorn, P. C. W., van der Burg, S. H., Gelderblom, H., & van Hall, T.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2010-02-24
Volume
127
Issue
4
Pages
899-909
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2124883011
Cited by
118
References
10
FWCI
2.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumors. https://app.cochat.ai/papers/10.1002/ijc.25113
The paper
van Dongen, M., Savage, N. D. L., Jordanova, E. S., Briaire‐de Bruijn, I. H., Walburg, K. V., Ottenhoff, T. H. M., Hogendoorn, P. C. W., van der Burg, S. H., Gelderblom, H., & van Hall, T. (2010). Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumors. International Journal of Cancer. https://doi.org/10.1002/ijc.25113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.